Introduction
Ozagrel can selectively inhibit thromboxane synthetase, thereby suppressing the production of thromboxane A2 and promoting the production of prostacyclin (PGI2), improving the balance between the two. Ultimately, it inhibits platelet aggregation, alleviates vascular spasm, and improves the microcirculation and energy metabolism disorders during local cerebral ischemia.
Specifications
In house/CP
Chemical Name
(E)-3-(4 - (1 - H - imidazol - 1 - ylmethyl) phenyl) - 2 - propenoic acid
Molecular formula
C13H12N2O2
CAS NO.
82571-53-7
Packing
1kg/tin
INDICATION
Suitable for the treatment of acute thrombotic cerebral infarction and motion disorders associated with cerebral infarction.
Category
Anticoagulant drugs
Storage
Protect from light, seal the container, and store in a cool place.
Pharmacological Actions
Inhibition of Thromboxane Synthesis
Ozagrel selectively inhibits thromboxane synthetase. This enzyme is crucial in the biosynthesis of thromboxane A₂, a potent vasoconstrictor and platelet aggregator. By blocking this enzyme, ozagrel reduces the production of thromboxane A₂.
Promotion of Prostacyclin Production
Concurrently, ozagrel has a promoting effect on the production of prostacyclin (PGI₂). Prostacyclin is a vasodilator and inhibitor of platelet aggregation. It counterbalances the effects of thromboxane A₂. The promotion of PGI₂ production by ozagrel helps to restore the balance between these two opposing factors in the body.
Overall Effects
Through the dual actions of inhibiting thromboxane A₂ production and promoting prostacyclin production, ozagrel effectively inhibits platelet aggregation. This prevents the formation of blood clots, which are often involved in the pathogenesis of cerebrovascular diseases. Additionally, it alleviates vascular spasm, improving blood flow in the affected blood vessels. Consequently, it helps to improve the microcirculation and energy metabolism disorders in the local cerebral ischemia area, reducing the damage to brain tissue caused by ischemia.
Clinical Applications
Ischemic Stroke
It is mainly used for the treatment of acute ischemic stroke. By improving cerebral blood flow and preventing further platelet aggregation and thrombosis, ozagrel can help reduce the size of the ischemic lesion and improve the neurological function of patients. It is often administered intravenously in the early stage of stroke to achieve the best therapeutic effect.
Other Applications
In addition to ischemic stroke, ozagrel may also be used in some other conditions related to abnormal platelet aggregation and vascular spasm, such as transient ischemic attacks and some peripheral vascular diseases. However, its use in these areas may be less common and requires further clinical studies to confirm its efficacy and safety.
Hot Tags: ozagrel, China ozagrel manufacturers, suppliers, factory, Artemether 71963 77 4, Ozagrel, Ozagrel Sodium, Abiraterone Acetate, Artemisinin 63968 64 9, Propiverine Hydrochloride












